Baloxavir marboxil
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329490

CAS#: 1985606-14-1

Description: Baloxavir marboxil, also known as S 033188, is an antiviral agent.


Price and Availability

Size Price Shipping out time Quantity
10mg USD 150 2 Weeks
25mg USD 250 2 Weeks
50mg USD 450 2 Weeks
100mg USD 750 2 Weeks
200mg USD 1250 2 Weeks
500mg USD 1650 2 Weeks
1g USD 1950 2 Weeks
2g USD 3450 2 Weeks
10g USD 7950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-06-06. Prices are subject to change without notice.

Baloxavir marboxil , purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329490
Name: Baloxavir marboxil
CAS#: 1985606-14-1
Chemical Formula: C27H23F2N3O7S
Exact Mass: 571.1225
Molecular Weight: 571.5518
Elemental Analysis: C, 56.74; H, 4.06; F, 6.65; N, 7.35; O, 19.59; S, 5.61


Related CAS #: 1985605-59-1 (Baloxavir)   1985606-14-1    

Synonym: Baloxavir marboxil; S 033188; S-033188; S033188; Xofluza;

IUPAC/Chemical Name: ({(12aR)-12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-6,8-dioxo-3,4,6,8,12,12ahexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl}oxy)methyl methyl carbonate

InChi Key: RZVPBGBYGMDSBG-GGAORHGYSA-N

InChi Code: InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1

SMILES Code: O=C(OCOC(C(C=C1)=O)=C(N1N([C@@H]2C3=CC=CC=C3SCC4=C(F)C(F)=CC=C24)[C@@]5([H])N6CCOC5)C6=O)OC


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Influenza vaccine for 2019-2020. Med Lett Drugs Ther. 2019 Oct 21;61(1583):161-166. PubMed PMID: 31770355.

2: Imai M, Yamashita M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Kiso M, Murakami J, Yasuhara A, Takada K, Ito M, Nakajima N, Takahashi K, Lopes TJS, Dutta J, Khan Z, Kriti D, van Bakel H, Tokita A, Hagiwara H, Izumida N, Kuroki H, Nishino T, Wada N, Koga M, Adachi E, Jubishi D, Hasegawa H, Kawaoka Y. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets. Nat Microbiol. 2019 Nov 25. doi: 10.1038/s41564-019-0609-0. [Epub ahead of print] PubMed PMID: 31768027.

3: Yoshino R, Yasuo N, Sekijima M. Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil. Sci Rep. 2019 Nov 25;9(1):17464. doi: 10.1038/s41598-019-53945-1. PubMed PMID: 31767949.

4: Kiso M, Yamayoshi S, Furusawa Y, Imai M, Kawaoka Y. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil. Viruses. 2019 Nov 15;11(11). pii: E1066. doi: 10.3390/v11111066. PubMed PMID: 31731678.

5: Seki M, Sakai-Tagawa Y, Yasuhara A, Watanabe Y. Adult influenza A (H3N2) with reduced susceptibility to baloxavir or peramivir cured after switching anti-influenza agents. IDCases. 2019 Oct 1;18:e00650. doi: 10.1016/j.idcr.2019.e00650. eCollection 2019. PubMed PMID: 31692637; PubMed Central PMCID: PMC6804930.

6: Ye C, Wang D, Liu H, Ma H, Dong Y, Yao M, Wang Y, Zhang H, Zhang L, Cheng L, Xu Z, Lei Y, Zhang F, Ye W. An Improved Enzyme-Linked Focus Formation Assay Revealed Baloxavir Acid as a Potential Antiviral Therapeutic Against Hantavirus Infection. Front Pharmacol. 2019 Oct 16;10:1203. doi: 10.3389/fphar.2019.01203. eCollection 2019. PubMed PMID: 31680975; PubMed Central PMCID: PMC6807675.

7: Hui DS, Ng SS. Recommended hospital preparations for future cases and outbreaks of novel influenza viruses. Expert Rev Respir Med. 2019 Oct 29:1-10. doi: 10.1080/17476348.2020.1683448. [Epub ahead of print] PubMed PMID: 31648548.

8: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK547923/ PubMed PMID: 31643258.

9: Leuba A, Lagnaux N, Cinoa A, Schnetz E, Genné D. [Antiviral therapy for general practitioners]. Rev Med Suisse. 2019 Oct 9;15(666):1825-1830. Review. French. PubMed PMID: 31599524.

10: Miskulin DC. Influenza in dialysis patients: an opportunity to decrease mortality? Curr Opin Nephrol Hypertens. 2019 Nov;28(6):607-614. doi: 10.1097/MNH.0000000000000550. PubMed PMID: 31567466.

11: Chesnokov A, Patel MC, Mishin VP, De La Cruz JA, Lollis L, Nguyen HT, Dugan V, Wentworth DE, Gubareva LV. Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir. J Infect Dis. 2019 Sep 21. pii: jiz472. doi: 10.1093/infdis/jiz472. [Epub ahead of print] PubMed PMID: 31541547.

12: Hirotsu N, Sakaguchi H, Sato C, Ishibashi T, Baba K, Omoto S, Shishido T, Tsuchiya K, Hayden FG, Uehara T, Watanabe A. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes. Clin Infect Dis. 2019 Sep 20. pii: ciz908. doi: 10.1093/cid/ciz908. [Epub ahead of print] PubMed PMID: 31538644.

13: Nemoto M, Tamura N, Bannai H, Tsujimura K, Kokado H, Ohta M, Yamanaka T. Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse. J Gen Virol. 2019 Nov;100(11):1471-1477. doi: 10.1099/jgv.0.001325. PubMed PMID: 31526451.

14: Takashita E, Ichikawa M, Morita H, Ogawa R, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, Sugawara H, Sato A, Akimoto M, Mitamura K, Abe T, Yamazaki M, Watanabe S, Hasegawa H, Odagiri T. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019. Emerg Infect Dis. 2019 Nov;25(11):2108-2111. doi: 10.3201/eid2511.190757. Epub 2019 Nov 17. PubMed PMID: 31436527; PubMed Central PMCID: PMC6810216.

15: Checkmahomed L, M'hamdi Z, Carbonneau J, Venable MC, Baz M, Abed Y, Boivin G. Impact of the baloxavir-resistant polymerase acid (PA) I38T substitution on the fitness of contemporary influenza A(H1N1)pdm09 and A(H3N2) strains. J Infect Dis. 2019 Aug 16. pii: jiz418. doi: 10.1093/infdis/jiz418. [Epub ahead of print] PubMed PMID: 31419295.

16: Szollosi DE, Bill A. Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza. Curr Drug Targets. 2019 Aug 1. doi: 10.2174/1389450120666190801115130. [Epub ahead of print] PubMed PMID: 31368872.

17: Gubareva LV, Fry AM. Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps. J Infect Dis. 2019 Jul 16. pii: jiz245. doi: 10.1093/infdis/jiz245. [Epub ahead of print] PubMed PMID: 31309982.

18: Uehara T, Hayden FG, Kawaguchi K, Omoto S, Hurt AC, De Jong MD, Hirotsu N, Sugaya N, Lee N, Baba K, Shishido T, Tsuchiya K, Portsmouth S, Kida H. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. J Infect Dis. 2019 Jul 16. pii: jiz244. doi: 10.1093/infdis/jiz244. [Epub ahead of print] PubMed PMID: 31309975.

19: Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, Hodges E, Jang Y, Barnes J, Uyeki T, Davis CT, Wentworth DE, Gubareva LV. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir(1). Emerg Infect Dis. 2019 Oct;25(10):1969-1972. doi: 10.3201/eid2510.190607. Epub 2019 Oct 17. PubMed PMID: 31287050; PubMed Central PMCID: PMC6759234.

20: Hussar DA. New Drugs 2019, part 3. Nursing. 2019 Aug;49(8):24-32. doi: 10.1097/01.NURSE.0000569740.20055.9e. PubMed PMID: 31268951.